Brigatinib: all 26 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
- Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsRecruitingNCT04925609Phase 1/2
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy AdultsCompletedNCT06132867Phase 1Results posted
- Brigatinib Before Brain Irradiation Trial (B3i Trial)TerminatedNCT04634110Phase 2Results posted
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedNCT03596866Phase 3Results posted
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Phase 2Results posted
- A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsCompletedNCT03420742Phase 1Results posted
- Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03410108Phase 2Results posted
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
- Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsTerminatedNCT02706626Phase 2Results posted
- A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02094573Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2Results posted
- Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerWithdrawnNCT05718297Phase 2
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownNCT05361564Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep PhenotypingCompletedNCT04318938Phase 2
- Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
- Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingNCT04227028Phase 1
- Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsActive, not recruitingNCT04223596Phase 2
- Brigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysActive, not recruitingNCT04074993Phase 2
- Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerTerminatedNCT04005144Phase 1
- Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersWithdrawnNCT03868423Phase 2
- Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
- Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03707938Phase 1